Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Non-Current Liabilities (2024 - 2025)

Century Therapeutics (IPSC) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 66.68% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.0 million through Dec 2025, down 66.68% year-over-year, with the annual reading at $61.0 million for FY2025, 66.68% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $61.0 million at Century Therapeutics, down from $67.6 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $194.3 million in Q2 2024, with the low at $61.0 million in Q4 2025.